Detail zboží

Veterinary Psychopharmacology, 2nd Edition

Stručný popis

Zcela revidované druhé vydání nabízí informace o terapii psychiatrických, psychologických a behaviorálních poruch u domácích mazlíčků. Jako přístupný zdroj je text rozdělen do sekcí o psychofarmakologických principech a klinické psychofarmakologii. Obsahuje podrobné informace o farmakologickém zásahu v oblasti duševního zdraví a chování domácích zvířat. Poskytuje důkladné vysvětlení možností a navrhuje, jaká léčiva by měla být předepsána a jak fungují. Aktualizované vydání zahrnovalo nejnovější poznatky v psychofarmakologii pro domácí zvířata. Zahrnuje nové kapitoly, které se týkají principů psychofarmakologie, různých serotonergních látek, antikonvulziv a stabilizátorů nálad, sympatolytických látek a antagonistů NMDA. Text vysvětluje možnosti léku, včetně všech informací nezbytných k nápravě dysfunkcí chemie mozku pomocí farmakologické léčby. Tento důležitý zdroj představuje aktualizovaný a komplexní zdroj pro farmakologické léčení psychiatrických poruch zvířat, koní a zoozvířat a poruch chování. Obsahuje podrobné informace o lécích, které podporují neurochemické změny, které změní náladu, emoční stav, reaktivitu a chování pacienta, včetně možností předepisování a mechanismů účinku. Zahrnuje nové kapitoly o zásadách psychofarmakologie, různých serotonergních látkách, stabilizátorech nálady, sympatolytických látkách a antagonisty NMDA.

Autor: Sharon L. Crowell-Davis, DVM, PhD, DACVB, is a Professor of Behavioral Medicine in the Department of Veterinary Biosciences and Diagnostic Imaging, College of Veterinary Medicine, the University of Georgia in Athens, Georgia, USA. Thomas F. Murray, PhD, is a Professor of Pharmacology and Provost of Creighton University in Omaha, Nebraska, USA. Leticia Mattos de Souza Dantas, DVM, MS, PhD, DACVB is a Clinical Assistant Professor of Behavioral Medicine at the University of Georgia Veterinary Teaching Hospital and the Department of Veterinary Biosciences and Diagnostic Imaging at the College of Veterinary Medicine, University of Georgia in Athens, Georgia, USA. She is also the Director and Co-founder of ZooPsych, Inc., a consultancy in Clinical Behavioral Medicine & Therapy in Georgia, USA.

Cena s DPH: asi 2968 Kč

Zboží není skladem

Koupit

Přesná cena bude sdělena na základě Vaší nezávazné objednávky.

Základní informace

Nakladatel	Wiley-Blackwell
ISBN	9781119226222
Vydání	II. vydání 2019
Vazba
Počet stran	336

Popis

Offers an updated second edition of the comprehensive reference on the use of drugs for veterinary mental health care and behavior modification

This fully revised Second Edition of Veterinary Psychopharmacology offers an authoritative reference to the drugs prescribed to treat psychiatric, psychological, and behavioral disorders in pets. Designed to be an accessible resource, the text is divided into sections on psychopharmacologic principles and clinical psychopharmacology. Comprehensive in scope, the book contains detailed information on pharmacologic intervention for pet mental health and behavior issues, offers thorough explanations of options, and explores why a particular drug should be prescribed and why it works.

Updated to include the recent advances in psychopharmacology for pets, the Second Edition includes new chapters that cover the principles of psychopharmacology, miscellaneous serotonergic agents, anticonvulsants and mood stabilizers, sympatholytic agents, and NMDA antagonists. In addition, the text explains the drug options, including all the information necessary to correct dysfunctions in the brain’s chemistry through pharmacologic treatment. This important resource:

• Presents an updated and comprehensive resource for pharmacologic treatments for pet, equine, and zoo animal psychiatric disorders and behavior problems

• Contains in-depth information on drugs that promote neurochemical changes that will alter the mood, emotional state, reactivity, and behavior of the patient, including prescribing options and mechanisms of action

• Includes new chapters on the principles of psychopharmacology, miscellaneous serotonergic agents, mood stabilizers, sympatholytic agents, and NMDA antagonists

Written for veterinarians, veterinary behaviorists, and veterinary students, the updated second edition of Veterinary Psychopharmacology is a complete source for current knowledge on pharmacologic behavior modification.

Obsah

Contributors xx	i
Preface	xxiii
Acknowledgments	xxv
Part I Principles of Veterinary Psychopharmacology	1
1 General Principles of Psychopharmacology	3
Thomas F. Murray Drug Action	3
Dose Dependence of Drug Interaction with Receptors	4
Structural Features of the Central Nervous System (CNS) and Neurotransmission	5
Biogenic Amine Neurotransmitters and Affective Disorders	8
2 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines	11
Thomas F. Murray Introduction	11
Glutamatergic Synapses	11
Pharmacology of Ketamine and Tiletamine	14
GABAergic Synapses	15
3 Biogenic Amine Neurotransmitters: Serotonin	21
Thomas F. Murray Introduction	21
The Biogenic Amines	21
Serotonin	22
4 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine	29
Thomas F. Murray Acetylcholine	29
Norepinephrine	32
Dopamine	37
5 Neuropeptides: Opioids and Oxytocin	43
Thomas F. Murray Introduction	43
Endogenous Opioid Peptides	43
Oxytocin	47
Part II Practice of Veterinary Psychopharmacology	51
6 Introduction to Clinical Psychopharmacology for Veterinary Medicine	53
Sharon L. Crowell‐Davis and Leticia Mattos de Souza Dantas Introduction	53
Prescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994)	54
Cost	55
Drug Selection	56
Medicating the Patient	57
Competition Animals	58
Taking the Behavioral History	58
The Behavioral Exam	63
Duration of Treatment	63
Limitations	64
7 Benzodiazepines	67
Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis Action	67
Overview of Indications	67
Contraindications, Side Effects, and Adverse Events	69
Overdose	69
Clinical Guidelines	69
Specific Medications	71
I. Alprazolam	71
II. Chlordiazepoxide HC1	73
IV. Clorazepate Dipotassium	78
V. Diazepam	80
VI. Flurazepam Hydrochloride	86
VII. Lorazepam	87
VIII. Oxazepam	89
IX. Triazolam	91
8 Selective Serotonin Reuptake Inhibitors	103
Niwako Ogata, Leticia Mattos de Souza Dantas, and Sharon L. Crowell‐Davis Action	103
Overview of Indications	103
Contraindications, Side Effects, and Adverse Events	104
Adverse Drug Interactions	104
Overdose	105
Clinical Guidelines	105
Specific Medications	106
I. Citalopram Hydrobromide	106
II. Fluoxetine Hydrochloride	108
III. Fluvoxamine	115
IV. Paroxetine Hydrochloride	117
V. Sertraline Hydrochloride	119
VI. Escitalopram Oxalate	122
9 Miscellaneous Serotonergic Agents	129
Leticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis Introduction	129
Azapirones	129
Action	129
Overview of Indications	129
Contraindications, Side Effects, and Adverse Events	129
Adverse Drug Interactions	129
Overdose	129
Clinical Guidelines	129
Specific Medications	130
I. Buspirone	130
I. Trazodone Hydrochloride	135
10 Anticonvulsants and Mood Stabilizers	147
Sharon L. Crowell‐Davis, Mami Irimajiri, and Leticia Mattos de Souza Dantas Action	147
Overview of Indications	148
Clinical Guidelines	148
Specific Medications	148
I. Carbamazepine	148
II. Gabapentin	149
III. Pregabalin	152
11 Sympatholytic Agents	157
Niwako Ogata and Leticia Mattos de Souza Dantas Action	157
Overview of Indications	157
Contraindications, Side Effects, and Adverse Events	158
Overdose	159
Clinical Guidelines	159
Specific Medications	160
I. Clonidine	160
II. Detomidine	161
III. Dexmedetomidine	163
IV. Propranolol	165
12 N‐Methyl‐D‐Aspartate (NMDA) Receptor Antagonists	171
Niwako Ogata and Leticia Mattos de Souza Dantas Action	171
Overview of Indications	172
Contraindications/ Side Effects, and Adverse Events	172
Clinical Guidelines	173
Specific Medications	173
I. Dextromethorphan	173
II. Amantadine	175
III. Memantine	176
IV. Huperzine A	179
13 Monoamine Oxidase Inhibitors	185
Leticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis Action	185
Overview of Indications	186
Specific Medications	186
I. Selegiline Hydrochloride	186
14 Antipsychotics	201
Lynne Seibert and Sharon Crowell‐Davis Introduction	201
Action	201
Overview of Indications	202
General Pharmacokinetics	203
Contraindications, Side Effects, and Adverse Events	203
Overdose	203
Clinical Guidelines	204
Specific Medications	204
I. Acepromazine Maleate	204
II. Azaperone	206
III. Chlorpromazine	206
IV. Clozapine	207
V. Fluphenazine	208
VI. Haloperidol	209
VII. Pimozide	210
VIII. Promazine	211
IX. Sulpiride	211
X. Thioridazine	212
15 CNS Stimulants	217
Sharon L. Crowell‐Davis Action	217
Overview of Indications	217
Contraindications, Side Effects, and Adverse Events	217
Adverse Drug Interactions	217
Overdose	217
Clinical Guidelines	218
Specific Medications	219
I. Amphetamine	219
II. Atomoxetine HCl	221
III. Methylphenidate Hydrochloride	223
16 Tricyclic Antidepressants	231
Sharon L. Crowell‐Davis Action	231
Overview of Indications	231
Contraindications, Side Effects, and Adverse Events	232
Adverse Drug Interactions	232
Overdose	232
Discontinuation	233
Clinical Guidelines	233
Specific Medications	233
I. Amitriptyline	233
II. Clomipramine Hydrochloride	236
III. Desipramine	243
IV. Doxepin	244
V. Imipramine	246
VI. Nortriptyline	248
17 Opioids and Opioid Antagonists	257
Leticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis Action	257
Overview of Indications	257
Contraindications, Side Effects, and Adverse Events	258
Clinical Guidelines	258
Specific Medications	258
I. Nalmefene	258
II. Naloxone HCl	260
III. Naltrexone Hydrochloride	261
IV. Pentazocine	264
18 Hormones	269
Sharon L. Crowell‐Davis Introduction	269
Oxytocin	270
Clinical Pharmacology	270
Indications	270
Side Effects	270
Doses in Nonhuman Animals	270
Effects Documented in Nonhuman Animals	270
Progestins	270
Action	270
Overview of Indications	271
Contraindications, Side Effects, and Adverse Events	271
Overdose	271
Clinical Guidelines	272
Specific Medications	272
I. Medroxyprogesterone Acetate (MPA)	272
II. Megestrol Acetate	273
19 Combinations	281
Leticia Mattos de Souza Dantas, Sharon L. Crowell‐Davis, and Niwako Ogata Introduction	281
Overview of Drug Augmentation	281
Potentially Beneficial Combinations	282
Adverse Interactions and Contraindications	283
Changing and Weaning Patients off Medications	285
Cytochrome P450 (CYP)	285
Interactions That Can Affect Dosing	285
Algorithms: Possible Future Direction	286
Conclusion	288
Index	291